| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Apr, 2026 | Apr, 2026 |
| Sales | 803,790 | 516,680 | 333,890 | 0 | 0 |
| Sales Growth | +55.57% | +54.75% | unch | unch | unch |
| Net Income | -7,130 | 32,930 | 3,460 | 0 | 0 |
| Net Income Growth | -121.65% | +851.73% | unch | unch | unch |
Telix Pharmaceuticals Limited ADR (TLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Telix Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Th company is developing a portfolio of clinical and commercial stage products which aims to address significant unmet medical needs in oncology and rare diseases. Telix Pharmaceuticals Limited, formerly known as TLX PHARMACEUT, is based in MELBOURNE, Australia.
Fiscal Year End Date: 12/31